European Archives - Page 669 of 1332 - European Medical Journal

First malaria vaccine granted WHO prequalification

The World Health Organization (WHO) has granted the first prequalification for a malaria vaccine to GSK’s Mosquirix in an important step toward immunising children against the disease.

EMJ announces partnership with the World Telehealth Initiative

EMJ is joining forces with the World Telehealth Initiative to support their mission to provide sustainable medical expertise through volunteer physicians…

Meet GOLD’s new catalyst – medical aficionado Juby Jacob-Nara

An exclusive version of our conversation Juby Jacob-Nara (Sanofi) about how former physicians can empower themselves to succeed in the pharmaceutical industry.

Latest updates in Advanced Systemic Mastocytosis from EHA 2022

Latest updates in Advanced Systemic Mastocytosis from EHA 2022. Targeting systemic mastocytosis. Update in Haematology session EHA 2022, Prof. Olivier Hermine introduces the session on overcoming the challenges in diagnosis and management of advanced systemic macrocytosis.

COVID-19 and Antimicrobial Resistance

For decades, infectious disease and public health experts have recognised antimicrobial resistance (AMR) and resulting infections due to multidrug resistant organisms as a persistent and increasingly urgent threat to public health at the local, national, and global level.

Driving post-conference motivation in pharma: a how-to guide

How can pharma embrace post-conference momentum?

Gene Therapy in Haemophilia: Updates from Clinical Trials and Insights to Future Technologies

At the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress, held 9th–13th July, multiple oral and poster presentations were dedicated to gene therapy as a treatment for haemophilia A or B.

EMJ Hematology 10 [Supplement 5] 2022

This article covers multiple oral and poster presentations dedicated to gene therapy as a treatment for haemophilia A and B, which took place at the International Society on Thrombosis and Haemostasis (ISTH) Congress, 9th–13th July 2022.

Driving Dermatology Research

This week, Jonathan sits down with Robert Dellavalle, Professor of Dermatology, Colorado School of Medicine, Aurora, USA.

Update on New Antigens in the Pathogenesis of Membranous Nephropathy

Previously, membranous nephropathies were divided into primary and secondary categories when the exact mechanism or pathogenetic factor were unknown. Approximately 70% accounted for primary membranous nephropathies. The remaining 30% were called secondary because they developed due to well-known diseases such as autoimmune diseases, tumours, infections, or drug assumptions.